Want to see SE:SEDANA full AI Analyst Report?
Top Page
Sedana Medical AB
(SEDANA)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr10.50
▼(-17.32% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance—material TTM revenue decline, ongoing operating losses, and sustained negative operating/free cash flow—despite a strong low-debt balance sheet. Technicals add support due to an uptrend above major moving averages and positive MACD, but overbought RSI/Stoch temper the outlook. Valuation is constrained by the company’s loss-making profile (negative P/E) and lack of a provided dividend yield.
Positive Factors
Low Leverage
Extremely low leverage and a substantial equity cushion reduce solvency risk and preserve financial flexibility. This balance-sheet strength can help Sedana continue investing in commercialization and clinical adoption while limiting dependence on creditors during periods of operating pressure.
Negative Factors
Revenue Contraction
The sharp TTM revenue decline indicates that recent commercial momentum has weakened after several years of growth. Persistent contraction would reduce the scale benefits available from the company’s fixed commercial infrastructure and make the route to sustainable profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Extremely low leverage and a substantial equity cushion reduce solvency risk and preserve financial flexibility. This balance-sheet strength can help Sedana continue investing in commercialization and clinical adoption while limiting dependence on creditors during periods of operating pressure.
Read all positive factors
Sedana Medical AB (SEDANA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.05B
Dividend YieldN/A
Average Volume (3M)246.74K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth-0.34%
EPS Growth29.54%
CountrySE
Employees117
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.36
Shares Outstanding99,336,960
10 Day Avg. Volume190,241
30 Day Avg. Volume246,739
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr209.00M
Sedana Medical AB Business Overview & Revenue Model
Company Description
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medic...
How the Company Makes Money
Sedana Medical makes money primarily by selling products used for inhaled ICU sedation. Key revenue streams include: (1) sales of its proprietary disposable administration device (Sedaconda ACD/ACD-S), which is used in the ventilator circuit to de...
Sedana Medical AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 195.46M | 200.23M | 178.75M | 153.87M | 122.86M | 159.15M |
| Gross Profit | 140.69M | 142.71M | 126.14M | 108.98M | 86.07M | 106.71M |
| EBITDA | -5.18M | -10.12M | -4.03M | -51.67M | -64.87M | -48.80M |
| Net Income | -35.83M | -59.24M | -10.67M | -59.61M | -73.51M | -57.97M |
Balance Sheet | ||||||
| Total Assets | 937.51M | 954.46M | 1.02B | 1.01B | 1.08B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 51.79M | 90.98M | 193.96M | 381.80M | 607.74M | 836.18M |
| Total Debt | 7.32M | 4.70M | 5.92M | 4.31M | 8.74M | 8.87M |
| Total Liabilities | 49.06M | 53.68M | 61.17M | 44.06M | 52.43M | 66.12M |
| Stockholders Equity | 888.45M | 900.78M | 958.26M | 970.00M | 1.03B | 1.10B |
Cash Flow | ||||||
| Free Cash Flow | -58.67M | -75.19M | -186.77M | -206.95M | -253.22M | -151.48M |
| Operating Cash Flow | -11.33M | -12.78M | -11.77M | -38.06M | -115.43M | -41.22M |
| Investing Cash Flow | -62.39M | -63.03M | -44.67M | -321.96M | -137.78M | -110.25M |
| Financing Cash Flow | -4.25M | -4.04M | -3.57M | -4.86M | -1.51M | 605.07M |
Sedana Medical AB Technical Analysis
Neutral
12.70
Price Trends
10.27
Positive
9.73
Positive
9.72
Positive
Market Momentum
0.03
Positive
43.83
Neutral
7.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Neutral. The current price of 12.7 is above the 20-day moving average (MA) of 11.33, above the 50-day MA of 10.27, and above the 200-day MA of 9.72, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 43.83 is Neutral, neither overbought nor oversold. The STOCH value of 7.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SEDANA.
Sedana Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr64.22B | 23.85 | 8.88% | 2.03% | -3.56% | 79.60% | |
71 Outperform | kr8.13B | 89.11 | 4.13% | ― | 8.79% | -20.48% | |
54 Neutral | kr1.05B | -28.88 | -3.99% | ― | -0.34% | 29.54% | |
52 Neutral | kr364.08M | -7.74 | -22.23% | ― | 6.49% | 25.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr565.96M | -66.25 | -2.84% | ― | -13.72% | 52.47% | |
43 Neutral | kr499.16M | -4.82 | -37.43% | ― | 27.40% | 26.07% |
* Healthcare Sector Average
SE:SEDANA
Sedana Medical AB
10.32
-2.56
-19.88%
SE:GETI.B
Getinge
234.40
27.68
13.39%
SE:SEZI
Senzime AB
3.42
-3.04
-47.06%
SE:XVIVO
Xvivo Perfusion AB
250.40
74.60
42.43%
SE:BACTI.B
Bactiguard Holding AB
15.90
-10.10
-38.85%
SE:BRAIN
BrainCool AB
0.90
-0.01
-1.10%
Sedana Medical AB Corporate Events
Sedana Medical Secures FDA PDUFA Date for Inhaled ICU Sedation Therapy
Aug 31, 2026
Sedana Medical AB has received a U.S. Food and Drug Administration Prescription Drug User Fee Act target action date of April 16, 2027 for its New Drug Application covering isoflurane delivered via the Sedana Medical ACD Delivery System for sedati...
Sedana Medical Wins FDA Review of Inhaled Sedation Drug for ICU Use
Aug 19, 2026
Sedana Medical AB said the U.S. Food and Drug Administration has accepted for review its New Drug Application for isoflurane delivered via the Sedana Medical ACD Delivery System to sedate mechanically ventilated adult ICU patients. The filing, sup...
Sedana Medical Narrows Losses as Margin Strength Offsets Weak Sales
Jul 17, 2026
Sedana Medical reported largely flat second-quarter 2026 sales, with net sales dipping 1% to MSEK 49.1 but gross margin improving to 73% from 70%. EBITDA losses narrowed to MSEK -1.9, and EBITDA excluding U.S. activities turned positive, reflectin...
Sedana Medical Sets July 17 Date for Q2 2026 Interim Report and Investor Presentation
Jul 3, 2026
Sedana Medical AB, a Stockholm-based medtech and pharmaceutical company listed on Nasdaq Stockholm, focuses on inhaled sedation for mechanically ventilated ICU patients through its Sedaconda ACD device and Sedaconda (isoflurane) drug. The company ...
Sedana Medical Names Mikael Haag as New CFO to Drive Expansion
Jun 17, 2026
Sedana Medical AB, listed on Nasdaq Stockholm and headquartered in Stockholm, develops and markets inhaled sedation solutions for intensive care, pairing its Sedaconda ACD device with the Sedaconda (isoflurane) drug and distributing them through a...
Sedana Medical Files FDA NDA for First Inhaled ICU Sedation Therapy in U.S.
Jun 17, 2026
Sedana Medical AB, a Stockholm-listed medtech and pharmaceutical group, focuses on inhaled sedation solutions that combine a proprietary delivery device with isoflurane for intensive care patients on mechanical ventilation. The company has built a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.